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ABSTRACT
Background: We have previously demonstrated that addition of omalizumab to standard therapy improved
asthma control by significantly improving lung function and reducing asthma exacerbations in Japanese pa-
tients with moderate-to-severe asthma. The aim of this study was to evaluate the effects of omalizumab on
long-term disease control in Japanese patients with moderate-to-severe persistent asthma.
Methods: An open-label, 48-week study was conducted in 133 Japanese patients with moderate-to-severe
persistent asthma. Omalizumab was administered subcutaneously every 2 or 4 weeks based on serum IgE
level and body weight in each patient.
Results: Treatment with omalizumab significantly improved lung function. A subgroup of patients with inade-
quately controlled severe persistent asthma, despite high dose inhaled corticosteroids and other multiple con-
troller therapies, which corresponds to the Japanese label (label population), showed greater improvements in
morning PEF and FEV1 than the whole study population (full Analysis Set). Serum free IgE levels decreased to
below the target and were maintained during the treatment period in almost all patients. The majority of adverse
events were mild-to-moderate in severity and there was no trend toward an increase in incidence of adverse
events with increase in duration of omalizumab. In addition, the profile of adverse events in this study was simi-
lar to that in a 16-week, placebo-controlled study which the present authors had conducted previously in Japan.
There were no anaphylactic reactions and no anti-omalizumab antibodies were detected.
Conclusions: Long-term treatment with omalizumab is effective and well tolerated in Japanese patients with
moderate-to-severe persistent asthma.
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INTRODUCTION
Asthma is the cause of a significant health, economic
and social burden, which increases with increasing
asthma severity. Patients with inadequately con-
trolled, severe asthma are at a particularly high risk
of exacerbations, hospitalization and death, and often
have severely impaired quality of life.1-6 In recent
years, several patient surveys have shown that many
patients with asthma remain poorly controlled around
the world, despite nationally promoted treatment
standards and improved therapeutic agents.7-9 In Ja-
pan, 2540 patients died from asthma in 200710 and the
annual mortality rate is higher than in the United
States or European countries.
Omalizumab, a recombinant humanized monoclo-
nal anti-IgE antibody, selectively binds to the Cε3 do-
main of IgE that interacts with IgE receptors.11 This
antibody blocks the binding of IgE to high affinity re-
ceptors on the effecter cells, thereby preventing the
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IgE-mediated cellular responses.12 In patients with
moderate-to-severe allergic asthma, omalizumab sig-
nificantly reduced the rate of exacerbations and
emergency visits for asthma and improved asthma re-
lated quality of life.13-20
As we had previously demonstrated the noticeable
clinical effects of omalizumab in a 16 week, random-
ized, double-blind, placebo-controlled study in Japa-
nese patients with moderate-to-severe persistent
asthma,21 we conducted further investigation on the
long-term efficacy and safety of omalizumab in Japa-
nese patients.
The objective of this 1-year, open-label study was to
evaluate the long-term efficacy and safety of omalizu-
mab in Japanese patients with moderate-to-severe
persistent asthma. In addition to the whole study
population [full analysis set (FAS)], we also focused
on a subgroup of patients with inadequately con-
trolled severe persistent asthma, despite high dose
inhaled corticosteroids (ICS) and other multiple con-
troller therapies, which corresponds to the Japanese
label (label population).
METHODS
PARTICIPANTS
Eligible patients were aged 20-75 years with
moderate-to-severe allergic asthma according to the
Japanese guidelines for diagnosis and management of
asthma,22 which is equivalent to the Global Initiative
for Asthma (GINA) Guidelines 2002,23 whose disease
was poorly controlled. Poor control was defined as
meeting one of the following criteria during the
screening period: 1) asthma symptom score of 2.0
every 2-week period, 2) use of rescue medication on
one day every 2-week period, 3) diurnal variation in
PEF of 20% on one day every 2-week period, 4)
FEV1 or mean PEF of 40 to 80% of predicted normal
value for the patient per week. All patients were re-
ceiving 400 μgday inhaled beclomethasone dipro-
pionate CFC (or equivalent) one month prior to the
screening period. Further inclusion criteria included
5) a positive skin test or in vitro reactivity to a peren-
nial aeroallergen or a serum total IgE level of more
than the normal value (170 IUmL), 6) a serum total
IgE level of 30 to 700 IUmL and body weight of 30 to
150 kg to allow optimal dosing of omalizumab.
Patients who had a history of the following were
excluded from the study: 1) active lung disease other
than allergic asthma, considered to interfere with the
evaluation; 2) use of immunosuppressants within 3
months of the first visit; 3) a history of severe anaphy-
lactoid or anaphylactic reactions; 4) positive reaction
to omalizumab in the skin test at screening; 5) preg-
nantnursing women; and 6) serious medical condi-
tions (e.g., cancer, hepatic failure, and renal failure).
STUDY DESIGN
This open-label study was conducted at 24 medical
centers in Japan and consisted of a 2-week screening
period, a 48-week treatment period, and a 12-week
follow-up period after final dosing.
Omalizumab (150 or 300 mg every 4 weeks or 225,
300, or 375 mg every 2 weeks) was administered to
patients subcutaneously based on their serum total
IgE level and body weight at baseline, which ensured
a minimum dose of 0.016 mgkgIgE (IUmL) every
4 weeks.24
The doses of ICS and other concomitant asthma
medications were kept constant during the screening
period and maintained during the treatment period as
much as possible. Use of rescue medication was per-
mitted as required throughout the study.
The study was conducted in accordance with the
current good clinical practice, and the protocol was
approved by each institutional ethics committee.
Prior to the onset of the study, a written informed
consent was obtained from all patients who were
enrolled. The study was registered at http:
clinicaltrials.gov with the identifier: NCT00219323.
EVALUATION OF EFFICACY
During the screening and treatment periods, morn-
ing PEF was measured by using a mini-Wright peak
flow meter (ATS scale) and the best of three meas-
urements was recorded daily in the patient diary.
Symptoms of asthma, daily activity and nocturnal
sleep limitations and use of asthma medications were
also recorded in the diary and scores (asthma symp-
tom score, daily activity score and sleep score) were
calculated according to the standard rating scale of
the Japanese Society of Allergology. Spirometry was
performed at baseline and at 12, 24, 36 and 48 weeks
of the treatment period.
SERUM FREE IgE LEVELS
Blood samples were collected for measurement of
free IgE at baseline and at 16, 24 and 48 weeks of the
treatment period. Free IgE were measured by ELISA
as previously described.25
EVALUATION OF SAFETY
Adverse events were examined throughout the treat-
ment period. Clinical laboratory tests were conducted
at baseline and at 4, 12, 16, 24, 36 and 48 weeks of the
treatment period. Anti-omalizumab antibodies (IgG
subtype) were measured by using solid-phase ELISA
at baseline and 12 weeks post final dosing.26
STATISTICAL ANALYSIS
Statistical analyses were performed using data from
all patients who received at least 1 dose of omalizu-
mab [full analysis set (FAS)]. Outcomes were also
evaluated in a subgroup of patients with inadequately
controlled asthma, defined as 1) FEV1 or mean PEF
of 40 to 80% of predicted normal value each week, 2)
daily daytime asthma symptoms or 3) night-time
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Table 1 Baseline demographic and clinical characteristics
Label population†
( n = 37)
Ful analysis set
( n = 133)
Age (years)
(14.92)54.5(15.42)47.7Mean (SD)
(24-74)53(20-74)47Median (range)
Sex, n (%)
(48.6)18(54.1)72Male
(51.4)19(45.9)61Female
(12.08)57.2(11.90)61.2Weight (kg), mean (SD)
(31-680)240(31-680)210Total serum IgE (IU/mL), median (range)
(14.69)18.3(13.11)13.7Duration of asthma (years), mean (SD)
Smoking history, n (%)
(51.4)19(51.1)68Never smoked
(48.6)18(48.9)65Curent smoker or ex-smoker
GINA (2002) asthma severity, n (%)
0(3.8)5Mild
0(10.5)14Moderate
(100)37(85.7)114Severe
Profile of poor asthma control in the previous year
(29.7)11(18.0)24Patients with ≥1 emergency room visits, n (%)
(13.5)5(7.5)10Patients with ≥1 hospitalization, n (%)
(19.09)65.6(20.47)77.3FEV1 (% of predicted), mean (SD)
(102.49)284.9(114.17)343.3Morning PEF (L/min), mean (SD)
Equivalent BDP CFC dose (μg/day)
(657.1)1487(568.3)1026Mean (SD)
(800-3600)1600(400-3600)800Median (range)
Concomitant medications, n (%)
(78.4)29(40.6)54Long-acting β2-agonists
(81.1)30(59.4)79Sustained-release theophylines
(73.0)27(38.3)51Anti-leukotrienes
(35.1)13(10.5)14Oral corticosteroids
GINA, Global Initiative for Asthma; BDP, beclometasone dipropionate.
† A subgroup of patients with inadequately controled severe persistent asthma despite high dose inhaled corticosteroids and multiple 
other controler therapies, which coresponds to the Japanese label.
awaking at least once a week who were receiving
high-dose ICS plus additional controller medications
out of long-acting β2-agonist (LABA), theophylline,
anti-leukotriene or oral corticosteroids, which corre-
sponds to the Japanese label (label population).
The changes from baseline in morning PEF and
FEV1 in the FAS as well as in the label population
were summarized using summary statistics every 2
weeks, and 1 sample t-test with respect to the change
from baseline in morning PEF and FEV1 was per-
formed. Asthma symptom score, daily activity score
and sleep score at each week in the FAS and the
change from baseline were summarized using sum-
mary statistics every 2 weeks.
The safety and tolerability of the study drugs were
summarized using appropriate descriptive methods.
RESULTS
PATIENTS
A total of 133 patients were enrolled in this study.
Nine patients withdrew from the study; 5 due to ad-
ministrative problems, 2 patients due to adverse
events, 1 patient withdrew by consent and 1 patient
died. No patients discontinued due to unsatisfactory
therapeutic effects.
A summary of the demographic and baseline char-
acteristics are shown in Table 1. Thirty seven patients
were included in the label population. The majority of
patients (85.7% in the FAS and 100% in the label popu-
lation) had severe persistent asthma as defined by
the GINA guidelines 2002.23 Patients in the label
population had less controlled asthma, compared
with the FAS, despite receiving higher dose of ICS
and more additional controller medications.
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Fig. 1 Changes over time from baseline in mean morning PEF (A) and FEV1 (B). Data are means + SE. ＊P < 0.05, 
＊＊P < 0.01, ＊＊＊P < 0.001 compared with the baseline (one sample t-test). At baseline, mean (SD) PEF was 343.3 
L/min (114.18) in the ful analysis set (FAS) and 285.0 L/min (102.55) in the label population (A subgroup of patients with 
inadequately controled severe persistent asthma despite high dose inhaled corticosteroids and multiple other controler 
therapies, which coresponds to the Japanese label). Mean (SD) baseline FEV1 was 2.32 L (0.915) and 1.76 L 
(0.680), respectively.
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LUNG FUNCTION (MORNING PEF AND FEV1)
Changes over time from baseline in mean morning
PEF and FEV1 are shown in Figure 1A, B. Treatment
with omalizumab resulted in significant increases
from baseline in mean morning PEF. At week 48
(study completion), the mean change from baseline
in morning PEF was 13.7 Lmin (P < 0.001) in the
FAS and 19.7 Lmin (P = 0.028) in the label popula-
tion.
Significant improvements were also seen in the
changes from baseline in FEV1. The mean change
from baseline in FEV1 was 0.127 L (P = 0.031) in the
label population at the time of study completion.
Morning PEF and FEV1 further improved in the la-
bel population compared with the FAS (Fig. 1A, B).
ASTHMA SYMPTOM SCORE, DAILY ACTIVITY
SCORE AND SLEEP SCORE
Treatment with omalizumab led to improvements in
asthma symptom scores. Daily activity scores and
sleep scores at the time of study completion slightly
improved (lower) compared with baseline (Table 2).
SERUM FREE IgE LEVELS
Serum free IgE levels decreased markedly, compared
to the baseline levels, to below the target (50 ngmL)
at 16, 24, and 48 weeks of the treatment period in
almost all patients [127 of 128 (99.2%), 125 of 126
(99.2 %) and 128 of 131 (97.7%), respectively].
SAFETY
Overall, 131 of 133 (98.5 %) patients experienced at
least one adverse event. The majority of adverse
events were mild-to-moderate in severity and only 3
patients experienced severe adverse events.
The most common adverse events were nasopha-
ryngitis (63.2%), injection site reactions (35.3%), up-
per respiratory tract inflammation (21.1%) and head-
ache (18.8%) (Table 3). Injection site reactions were
the most frequently reported drug-related adverse
events occurring in a total of 38 (28.6 %) patients. All
of the injection site reactions were of a mild degree
and resolved without any additional treatment.
There was generally no trend toward an increase in
incidence of adverse events with an increase in dura-
tion of omalizumab (Table 4).
Six patients experienced serious adverse events;
these included 1 death due to an asthmatic attack. No
serious adverse events were considered to be drug-
related.
Two patients discontinued treatment prematurely
because of adverse events (urticaria and iron defi-
ciency anaemiahiatus hernia), which were of a se-
vere degree. Urticaria, which developed 10 days after
the first dose, was suspected to be drug-related and
resolved completely with additional treatments.
There were no anaphylactic reactions, and neither
evidence of immune complex disease, nor clinically
important abnormalities in vital signs and laboratory
tests were found. No anti-omalizumab antibodies
were detected.
Omalizumab in Japanese Patients with Asthma
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Table 2 Change from baseline in asthma symptom score, daily activity score and sleep score in the ful analysis set (FAS)
Sleep score
(n = 132)
Daily activity score
(n = 133)
Asthma symptom score
(n = 132)
Baseline
(13.23)10.2(26.74)18.9(17.42)15.5Mean (SD)
(0.0-56.0)3.2(0.0-112.0)0.0(0.0-119.8)11.0Median (range)
Change from baseline
n = 132n = 132n = 1328 weeks
(10.82)-0.2(18.24)0.4(15.97)-1.5Mean (SD)
(-28.3-32.0)0.0(-56.0-64.0)0.0(-43.5-112.8)-1.1Median (range)
n = 130n = 130n = 13016 weeks
(11.64)-1.6(19.80)-2.1(14.44)-4.8Mean (SD)
(-32.0-30.0)0.0(-96.0-59.4)0.0(-87.3-32.7)-2.9Median (range)
n = 125n = 125n = 12532 weeks
(10.57)-2.0(21.39)-3.4(17.01)-6.7Mean (SD)
(-32.0-36.0)0.0(-78.0-120.0)0.0(-110.3-33.5)-3.5Median (range)
n = 123n = 123n = 12348 weeks
(10.25)-2.3(16.89)-3.3(12.73)-6.2Mean (SD)
(-32.0-28.0)0.0(-56.0-56.0)0.0(-65.8-26.0)-4.0Median (range)
DISCUSSION
This is the first study investigating the long-term effi-
cacy and safety of omalizumab in Japanese patients
with moderate-to-severe persistent asthma.
Treatment with omalizumab provided significantly
improved lung function, which was maintained dur-
ing 48 weeks of the treatment period. Improvements
in morning PEF and FEV1 from baseline in the label
population were greater than in the FAS, though pa-
tients in the label population had lower lung function
at baseline, despite receiving higher-dose ICS and
more controller medications, including LABA and
oral corticosteroids, than the FAS. These results
could strongly support the potential role of omalizu-
mab in management of patients with inadequately
controlled asthma despite standard medications.
In addition to lung function, asthma symptom
scores also improved. Modest improvements in daily
activity score and sleep score may be because daily
activity or nocturnal sleep limitations were not man-
datory requirements in the inclusion criteria and
about half of the patients had baseline values of zero
in daily activity scores [50.4% (67 patients)] and in
sleep scores [45.5% (60 patients)], respectively.
These patients might have influenced the power to
detect the changes and in fact, greater improvements
in change from baseline were seen in subgroups of
patients with any scores at baseline (mean [SD] and
median [range]: -10.0 [20.65] and -8.0 [-56.0-39.4] for
daily activity scores, -6.6 [10.91] and -6.0 [-32.0-24.0]
for sleep scores, at study completion).
Though this was an open-label, uncontrolled study
and there are limitations in interpretations of the re-
sults, this study suggests that there is no evidence of
loss of efficacy with long-term omalizumab treatment.
As consistent with the efficacy results, serum free
IgE levels decreased markedly to below 50 ngmL at
16, 24, and 48 weeks of the treatment period in al-
most all patients.
One year treatment with omalizumab was gener-
ally well tolerated. The majority of adverse events
were of a mild-to-moderate degree and there was no
trend toward an increase in incidence of adverse
events with an increase in duration of omalizumab.
In addition, the profile of adverse events in this
study was similar to that in the omalizumab group in
the 16-week, placebo-controlled study21 which the
present authors had conducted previously in Japan.
Despite the longer treatment period in this study
compared with the previous study, the percentage of
patients experiencing 1 adverse events and 1
drug-related adverse events in this study was compa-
rable with that in the previous study [adverse events,
98.5% for this study and 90.1% (136 of 151) for the pre-
vious study; drug-related adverse events, 45.9% and
48.3% (73 of 151), respectively]. In both studies, the
most common adverse events were nasopharyngitis,
injection site reactions, upper respiratory tract inflam-
mation and headache. The most frequently reported
drug-related adverse events were also injection site
reactions [28.6% for this study and 33.1% (50 of 151)
for the previous study].
There were no cases of anaphylaxis and no cases of
significant immune complex-mediated disorders. No
anti-omalizumab antibodies were detected.
Therefore, there is no evidence that new or more
serious adverse events occur with long-term omalizu-
mab treatment.
Results of several large randomized studies13-21
have established omalizumab as an effective and well
tolerated agent for use as add-on therapy in patients
Ohta K et al.
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Table 3 Number (%) of patients with most frequently reported adverse events (≥5%) and drug-related adverse events (≥3%)
Ful analysis set
(n = 133)
n (%)
Prefered term System organ class
Adverse events (≥5%)
(98.5)131Total adverse events
(6.0)8EnterocolitisGastrointestinal disorders
(5.3)7Diarhoea
(5.3)7Gastritis
(5.3)7Toothache
(35.3)47Injection site reactionsGeneral disorders
(15.0)20Injection site erythemaand administration site conditions
(11.3)15Injection site sweling
(9.0)12Injection site pain
(7.5)10Injection site haemorhage
(7.5)10Injection site pruritus
(5.3)7Oedema peripheral
(63.2)84NasopharyngitisInfections and infestations
(12.0)16Acute bronchitis
(8.3)11Influenza
(6.0)8Pharyngitis
(6.0)8Dental caries
(5.3)7Gastroenteritis
(11.3)15C-reactive protein increasedInvestigations
(9.8)13White blood cel count increased
(6.0)8Glucose urine present
(5.3)7Alanine aminotransferase increased
(9.0)12Back painMusculoskeletal and connective tissue disorders
(18.8)25HeadacheNervous system disorders
(21.1)28Upper respiratory tract inflammationRespiratory, thoracic 
(5.3)7Pharyngolaryngeal painand mediastinal disorders
(6.0)8PruritusSkin and subcutaneous tissue disorders
(5.3)7Eczema
Drug-related adverse events (≥3%)
(45.9)61Total drug-related adverse events
(14.3)19Injection site erythemaGeneral disorders
(9.8)13Injection site swelingand administration site conditions
(6.8)9Injection site pruritus
(6.0)8Injection site pain
(3.8)5Injection site haemorhage
(3.8)5Injection site induration
(3.0)4Injection site warmth
(3.8)5Immunology test abnormalInvestigations
with severe persistent allergic asthma inadequately
controlled with high-dose ICS plus a LABA (Euro-
pean Union labeling) or those with moderate to se-
vere disease inadequately controlled with ICS
(United States labeling). Omalizumab has recently
(January 2009) been approved in Japan as an add-on
therapy for patients whose symptoms are inade-
quately controlled despite standard medications
(high-dose ICS plus additional controller medica-
tions), which is similar to the indication in the Euro-
pean Union. In addition, international asthma man-
agement treatment guidelines (by GINA23 and the
National Heart, Lung, and Blood Institute27) acknowl-
edge the importance of omalizumab as a treatment
option in these difficult-to-treat patient populations.
Further investigations will likely reveal additional
roles of IgE or mast cells in the pathophysiology of
severe asthma (e.g., remodeling of the airway wall),
as well as the therapeutic potential of omalizumab.
In conclusion, the results of this study indicate that
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Table 4 Adverse events in every 12 weeks (≥5%) in the ful analysis set (FAS)
Over al
(n = 133)
n (%)
37-48
(n = 125)
n (%)
25-36
(n = 129)
n (%)
13-24
(n = 131)
n (%)
0-12
(n = 133)
n (%)
Period (weeks)
System organ class
(98.5)131(68.8)86(69.0)89(79.4)104(79.7)106Total adverse events
(6.8)9(1.6)2(4.7)6(1.5)2(1.5)2Eye disorders
(31.6)42(12.0)15(11.6)15(11.5)15(15.8)21Gastrointestinal disorders
(42.9)57(9.6)12(16.3)21(19.1)25(25.6)34General disorders and 
administration site conditions
(76.7)102(33.6)42(32.6)42(45.0)59(40.6)54Infections and infestations
(6.8)9(1.6)2(3.1)4(2.3)3(0.8)1Injury, poisoning and procedural 
complications
(36.8)49(22.4)28(16.3)21(10.7)14(4.5)6Investigations
(25.6)34(6.4)8(9.3)12(6.9)9(7.5)10Musculoskeletal and connective 
tissue disorders
(24.1)32(3.2)4(7.8)10(7.6)10(13.5)18Nervous system disorders
(33.8)45(10.4)13(14.0)18(19.8)26(15.0)20Respiratory, thoracic and 
mediastinal disorders
(23.3)31(8.0)10(6.2)8(6.1)8(11.3)15Skin and subcutaneous tissue 
disorders
(5.3)7(0.8)1(2.3)3(0.8)1(1.5)2Vascular disorders
omalizumab is effective and well-tolerated in the long-
term control of Japanese patients with moderate-to-
severe persistent asthma.
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